cadisegliatin
AssetAlso NN-9108, NNC 0080-0000-3315, NNC 80-3315, TTP-00223399
Activates glucokinase in the liver to increase glucose uptake and improve blood glucose control.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Glycolysis
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Type 1 diabetes
Phase 3, globenewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.